Amgen (AMGN) versus Audentes Therapeutics (BOLD) Critical Contrast

Amgen (NASDAQ:AMGN) and Audentes Therapeutics (NASDAQ:BOLD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Earnings and Valuation

This table compares Amgen and Audentes Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amgen $23.75 billion 5.01 $8.39 billion $14.40 13.28
Audentes Therapeutics N/A N/A -$128.82 million ($3.40) -11.23

Amgen has higher revenue and earnings than Audentes Therapeutics. Audentes Therapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

78.1% of Amgen shares are owned by institutional investors. 0.3% of Amgen shares are owned by insiders. Comparatively, 6.6% of Audentes Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


This table compares Amgen and Audentes Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amgen 35.35% 66.74% 14.05%
Audentes Therapeutics N/A N/A -33.26%

Analyst Ratings

This is a summary of current ratings for Amgen and Audentes Therapeutics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen 0 9 8 0 2.47
Audentes Therapeutics 1 3 7 0 2.55

Amgen presently has a consensus target price of $205.69, indicating a potential upside of 7.56%. Audentes Therapeutics has a consensus target price of $32.77, indicating a potential downside of 14.20%. Given Amgen’s higher possible upside, equities research analysts clearly believe Amgen is more favorable than Audentes Therapeutics.


Amgen pays an annual dividend of $5.80 per share and has a dividend yield of 3.0%. Audentes Therapeutics does not pay a dividend. Amgen pays out 40.3% of its earnings in the form of a dividend. Amgen has increased its dividend for 8 consecutive years.

Risk and Volatility

Amgen has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Audentes Therapeutics has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500.


Amgen beats Audentes Therapeutics on 12 of the 16 factors compared between the two stocks.

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; and DaVita Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

About Audentes Therapeutics

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.